Salermide down-regulates sirtuin proteins to induce human cancer cell apoptosis
© Leisser et al; licensee BioMed Central Ltd. 2011
Published: 5 September 2011
The NAD+-dependent family of sirtuin proteins (SIRT1–7), is involved in cell apoptosis and senescence. Salermide is a potent inhibitor of SIRT1 and SIRT2 and can induce tumor-specific cell death in selected human cell lines. In this study we investigated salermide’s apoptotic effect in a wide range of other human cancer cell lines and its antiproliferative potential in combination with cisplatin.
Seven different cancer cell lines (SKOV-3, MKN45, MKN28, N87, FaDu, NuLi1, Jurkat) were treated with salermide (1 µM – 0.1 nM) for 24, 48, and 72 hours and assessed for cell viability. Three cell lines (SKOV-3, N87, Jurkat) were selected for combination therapy with salermide and cisplatin (30 µM). In order to characterize salermide’s proapoptotic pathway SIRT1, SIRT2, pAKt, p53, acetyl-p53 and Nampt (nicotinamide phosphoribosyltransferase) were determined in SKOV-3 and Jurkat cells by Western blotting.
Salermide yielded greater dose-dependent apoptotic effects in Jurkat, SKOV-3 and N87 cells than in the other cell lines, with most potent effect after 48 h of incubation. The anti-proliferative activity was associated with a G0-G1 cell cycle arrest. SIRT1 and SIRT2 protein were down-regulated after 48 h and 72 h. This was accompanied by a down-regulation of pAKT, p53 and Nampt. Acetyl-p53 levels were not consistent across cell types. Cisplatin exerted synergistic effects with salermide in all cell lines and reduced cell viability up to 50%.
Salermide-induced apoptosis is cell line-dependent and more effective in slow-proliferating (SKOV-3) and hematologic (Jurkat) cancer cells. The synergism with cisplatin implies a potentiating effect of this sirtuin inhibitor as add-on in clinical cancer therapy.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.